The increasing incidence of orthopaedic methicillin-resistant Staphylococcus aureus (MRSA) infections represents a significant therapeutic challenge. Being effective against MRSA, the role of vancomycin may become more important in the orthopaedic setting in the years to come. Nonetheless, vancomycin bone and soft tissue penetration during infection remains unclear. In eight pigs, implant-associated osteomyelitis was induced on day 0, using a Staphylococcus aureus strain. Following administration of 1,000 mg of vancomycin on day 5, vancomycin concentrations were obtained with microdialysis for 8 h in the implant bone cavity, in cancellous bone adjacent to the implant cavity, in subcutaneous adipose tissue (SCT) adjacent to the implant cavity, and in healthy cancellous bone and healthy SCT in the contralateral leg. Venous blood samples were also obtained. The extent of infection and inflammation was evaluated by post-mortem computed tomography scans, C-reactive protein serum levels and cultures of blood and swabs. In relation to all the implant cavities, bone destruction was found. Ranging from 0.20 to 0.74, tissue penetration, expressed as the ratio of the area under the concentration-time curve from 0 to the last measured value, was incomplete for all compartments except for healthy SCT. The lowest penetration was found in the implant cavity. In conclusion, Staphylococcus aureus implantassociated osteomyelitis was found to reduce vancomycin bone penetration, especially in the implant cavity. These findings suggest that it may be unsafe to rely solely on vancomycin therapy when treating acute osteomyelitis. Particularly when metaphyseal cavities are present, surgical debridement seems necessary. ß
Implant-associated osteomyelitis and periprosthetic joint infections are devastating complications of joint replacement surgery. It is projected that up to 4 million joint arthroplasties will be completed in the UK and USA by 2030, and up to 5% of these patients will develop an infection around the implant. [1] [2] [3] Treatment is a specialist-assignment and involves a combination of surgical debridement and prolonged antimicrobial therapy. Treatment failure is common and may partly be a consequence of lack of knowledge regarding target-site penetration of antimicrobials. 4, 5 Plasma pharmacokinetic/pharmacodynamic (PK/PD) targets have been established for most antimicrobials but specific tissue PK/PD targets are widely unknown. 6 Particularly, in tissues with infection and inflammation, PK/PD targets are often not existing. In cases with insufficient tissue penetration, dosing based on plasma concentrations may therefore lead to treatment failures. Bone infection induces intra-trabecular suppuration which results in ischemic osseous sequestration and reduced vascularization. 7 Accordingly, it seems rational to hypothesize that antimicrobial bone penetration to infected bone decreases with the progression of infection and inflammation.
The predominant pathogen in orthopaedics is Staphylococcus aureus. Over the last decade, the incidence of orthopaedic methicillin-resistant Staphylococcus aureus (MRSA) infections has increased markedly. 8, 9 Being effective against MRSA, vancomycin is recommended as first-line choice for treatment of orthopaedic MRSA infections. [10] [11] [12] Vancomycin bone pharmacokinetics has almost solely been investigated using bone biopsies, and only few studies have assessed the impact of infection and inflammation. [13] [14] [15] [16] The bone biopsy approach suffers from methodological challenges, which may reduce the applicability of the findings. Indeed, large variations in tissue concentrations have been found. 13, 17, 18 In recent years, the pharmacokinetic tool microdialysis (MD) has successfully been applied for sampling of various antimicrobials in drill holes in bone. [19] [20] [21] [22] [23] [24] [25] [26] The objective of this study was to evaluate the effect of a traumatically induced, implant-associated acute osteomyelitis on vancomycin bone penetration in a porcine model.
27

MATERIALS AND METHODS
The study was approved by the Danish Working Environment Authority and The Danish Animal Experiments Inspectorate, and was carried out in accordance with existing laws (license No. 2013/15-2934-00946). The study was performed on a previously described osteomyelitis porcine model and analogous to a former study where cefuroxime was the study drug. 26, 27 Overview Eight female pigs (Danish Landrace breed, weighing from 75 to 86 kg) were included in the study. They all went through two surgeries (day 0 and 5). On day 0, traumatically induced implant-associated S. aureus osteomyelitis was induced in the proximal metaphysis of the right tibia. On day 5 sampling of vancomycin was performed using MD in the implant bone cavity, in cancellous bone adjacent to the implant cavity (ADJ-I cancellous bone), in subcutaneous adipose tissue adjacent to the implant cavity (ADJ-I SCT), and in healthy cancellous bone and healthy SCT in the contralateral leg. Venous blood samples were also collected from a central venous catheter. Following surgery and calibration of the MD probes, 1,000 mg of vancomycin ("Hospira," Sweden) was administered intravenously in a peripheral catheter over 100 min. Sampling was conducted over 8 h starting at the beginning of vancomycin infusion. Tissue penetration ratios were the primary endpoint. Secondary endpoints were standard PK parameters; the area under the concentration-time curves (AUC 0-last ), peak drug concentration (C max ), and time to C max (T max ). After the last samples were collected, the pigs were euthanized using pentobarbital.
Study Procedures
Bacterial Strain A concentration of 10 4 colony-forming units of a betahemolytic S. aureus (non MRSA) strain S54F9 of spa type t1333 (spaserver.ridom.de) in a 10-ml saline solution was used for inoculation. 28 
Anesthesia
Induction of anesthesia on day 0 and 5 and postoperative care was effected as previously described. 26 A combination of fentanyl (0.35-0.5 mg/h, continuous infusion) and propofol (10-15 mg/kg/h, continuous infusion) maintained the anesthesia during surgery and the sampling period.
Induction of Implant-Associated Osteomyelitis, Surgery 1 on Day 0 In lateral position, under sterile conditions and fluoroscopic guidance, a cavity was created in cancellous bone of the anteromedial aspect of the right proximal tibia. The cavity was placed parallel to and approximately 10 mm distal to the epiphyseal line and created using a 4-mm Kirschner wire. The depth of the cavity was aimed to be 27 mm. 10 ml of inoculum was injected to the cavity and an implant of a 20 Â 2 mm Kirschner wire was introduced. Periosteum, subcutaneous adipose tissue, and skin were closed in separate layers.
Implantation of Microdialysis Probes, Surgery 2 on Day 5
On day 5, all animals had developed subcutaneous abscesses adjacent to the implant cavity. Again, in the lateral position and under sterile conditions, the proximal tibia was exposed via the incision from surgery 1. This also led to drainage of the abscesses. Approximately 8 mm parallel to the implant cavity and 10 mm distal to the epiphyseal line, and under fluoroscopic guidance, another drill hole with a diameter of 2 mm and a depth of 27 mm was made, simulating adjacent infected cancellous bone. The pig was then placed in its opposite side, to drill an identical hole in contralateral, healthy, left tibia. Next, the pig was placed in supine position, and MD probes were placed in the SCT: parallel to and 10 mm distal to the skin incision on both the infected and healthy leg using the manufacturers standard introducer. MD probes were then placed in the drill holes bilaterally and in the implant cavity. The periosteum above the implant cavity was intact, and was perforated with a cannula before introduction of the MD probe. The perforation did not lead to drainage of the cavity. To prevent displacement, the skin was closed and all probes were fixed to the skin with single sutures. For each MD-location, the following membrane lengths were used: Implant cavity (20 mm), ADJ-I cancellous bone (20 mm), ADJ-I SCT (30 mm), cancellous bone (20 mm), and SCT (30 mm). Correct location of the bone probes was assessed by fluoroscopy.
Assessment of Infection
The extent of infection was evaluated by C-reactive protein (CRP) level in serum, cultures of blood, swabs from the implant cavity, ADJ-I cancellous bone, and ADJ-I SCT and post-mortem computed tomography (CT) scans. The CT scans were used to evaluate destruction of the bone surrounding the implant cavity by measuring the increase of diameter and volume of the cavity.
Microdialysis and Sampling Procedures
A thorough description of MD can be found elsewhere. 29, 30 In brief, MD is a probe-based method enabling continuous sampling of water-soluble molecules from the tissue of interest. 19, 21, [31] [32] [33] [34] Owing to the continuous perfusion and the semipermeable membrane at the tip of the probe, a nonequilibrium diffusion of molecules following the concentration gradient will occur. Thus, the dialysate-concentrations act only as a fraction of the actual concentration; expressed as relative recovery (RR). All MD probes were individually calibrated using retrodialysis. 35 The MD system in the present study consisted of CMA 107 precision pumps (m-Dialysis AB, Stockholm, Sweden) and CMA 70 probes (membrane length 30 and 20 mm, molecular cut-off 20 kilo Daltons). After surgery, all MD probes, except for the implant cavity-probes, were perfused with 0.9% NaCl containing vancomycin at a concentration of 2.5 mg/ml at a perfusion rate of 1 mL/min. The implant cavity-probes were perfused with pure 0.9% NaCl after surgery and throughout the sampling time. Following a 30-min tissue equilibration period, all probes, except for the implant cavity-probes, were individually calibrated by collecting a 60-min sample. After calibration, the perfusate was changed to blank isotonic saline, and a 180-min washout period was allowed for. The implant cavity-probes were calibrated with 0.9% NaCl containing vancomycin at a concentration of 100 mg/ml when the last dialysate was collected. This approach was applied to avoid falsy high levels of vancomycin in a presumably poorly perfused cavity. 1,000 mg of vancomycin was then administered intravenously in a peripheral catheter over 100 min. From time 0-120 min dialysates were collected every 40 min and thereafter every 60 min from 120 to 480 min, giving a total of nine samples over 8 h. Venous blood samples were collected from a central venous catheter in the middle of every dialysate sampling interval.
Dialysates were immediately frozen on dry ice and were then transferred to a À80˚C freezer until analysis. Dialysate concentrations were corrected for RR and attributed to the midpoint of each sampling interval. Venous blood samples were stored at 5˚C for a maximum of 24 h before being centrifuged at 3,000g for 10 min. Plasma aliquots were then frozen and stored at À80˚C until analysis.
Quantification of Vancomycin Concentrations
Dialysate concentrations were determined using Ultra High Performance Liquid Chromatography (UHPLC) as previously 1094 BUE ET AL.
described. 24 The limit of quantification was defined as the lowest concentration with intra run CV <20%, and was found to be 0.05 mg/ml. The free concentration of vancomycin in plasma was measured on the Cobas c501 platform (Roche, Switzerland).
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Pharmacokinetic Analysis and Statistics
The pharmacokinetic (PK) parameters AUC 0-last , C max , T max and terminal half-life (T 1/2 ), were determined separately for each subject by non-compartmental analysis (NCA) using the pharmacokinetic-series of commands in Stata (v. 14.1). The area under the concentration-time curves (AUC 0Àlast ) was calculated using the trapezoidal rule. C max was calculated as the maximum of all the recorded concentrations, and T max as the time to C max . T 1/2 was calculated as ln(2)/ l eq , where l eq is the terminal elimination rate constant estimated by linear regression of the log concentration on time. The variables AUC 0-last , C max , T max and T 1/2 were analyzed using their log transformed data in a mixed model taking the variance between the pigs into account. Consequently, after back-transforming to the original scale, medians and 95%CIs of AUC 0-last , C max , T max and T 1/2 are given. The model assumptions were tested by visual diagnosis of residuals, fitted values and estimates of random effects. A correction for degrees of freedom due to small sample size was handled using the Kenward-Roger approximation method. Overall comparisons between the compartments were conducted using F test and pairwise comparisons using t-test. A p-value <0.05 was considered significant. No correction for multiple comparisons was applied. The tissue AUC 0-last to plasma AUC 0-last ratio (AUC tissue /AUC plasma ) was calculated as a measure for tissue penetration. Statistical analyses were also performed using Stata. Values below lower limit of quantification were set to zero. The washout concentrations were low, and therefore not included in the analysis.
RESULTS
All eight pigs completed the study. Dialysate concentrations could not be reliably determined for one implant cavity-probe, due to UHPLC apparatus failure, and this probe was therefore excluded from the analysis. For three cancellous bone probes, and one ADJ-I SCT probe, RR could not be reliably determined. The dialysate concentrations for these probes resembled the dialysate concentrations of the other probes from the same locations. For probes where RR could not be determined, mean RR from the same locations were therefore used to obtain absolute tissue concentrations. Flouroscopy confirmed correct placement of all probes.
S. aureus was re-isolated from seven of eight implant cavity swabs, six of eight ADJ-I SCT swabs and three of eight ADJ-I cancellous bone drill-holes. Five of eight implant cavity swabs were typed to the infecting strain. No bacteria were isolated from the blood. Mean CRP (AESD) increased from 20.9 AE 12.6 mg/l at day 0 (before bacterial inoculation) to 120.7 AE 99.1 mg/l at day 5.
Bone destruction was found in relation to all the implant cavities as shown by the increase in diameter of the implant cavity from 4 mm to a mean (AESD) of 5.6 AE 1.4 mm and an increase of volume (AESD) of 1.13 AE 1.04 cm 3 . No radiologic changes in the bone surrounding the ADJ-I cancellous drill hole were observed. A representative intraoperative fluoroscopy image and post-mortem CT sectional views of the implant cavity, drill hole in ADJ-I cancellous bone and drill hole in healthy cancellous bone from one pig are illustrated in Figure 1 .
Mean (AESD) RRs were 21.3 AE 12.3% (cancellous bone), 29.5 AE 11.0 % (ADJ-I cancellous bone), 26.5 AE 6.0 (SCT), 36.7 AE 17.7% (ADJ-I SCT), and 40.0 AE 6.3% (implant cavity).
Vancomycin plasma and tissue concentration-time profiles are shown in Figure 2 . Corresponding key pharmacokinetic parameters are provided in Table 1 . Ranging from 0.20 to 0.74, tissue penetration (expressed as the ratio of AUC tissue /AUC plasma ) was incomplete for all compartments except for SCT. The lowest penetration was found in the implant cavity. AUC 0-last for the implant cavity was also significantly lower than all the other compartments (p < 0.03). Accordingly, C max for the implant cavity differed from the remaining (p < 0.03), except for ADJ-I cancellous bone (p ¼ 0.062). Finally, AUC 0-last and C max were lower in ADJ-I cancellous bone compared with healthy cancellous bone, although not significantly (p < 0.089).
DISCUSSION
Management of osteomyelitis traditionally involves a combination of surgical debridement and longstanding antimicrobial therapy, but recently there has been a trend toward antimicrobial therapy alone. 36, 37 The success of antimicrobial treatment alone obviously relies upon sufficient target site penetration. Findings like metaphyseal cavities and subperiosteal abscesses are usually considered indicators of insufficient antimicrobial target site penetration. In this study, singledose vancomycin tissue penetration was evaluated in a porcine model where implant associated osteomyelitis was induced in the proximal tibial metaphysis. Bone destruction was observed around the implant resembling a metaphyseal cavity. The main finding was that implant cavity vancomycin penetration was significantly incomplete and lower than all the other compartments. In fact, the vancomycin tissue distribution in general was rather heterogeneous, and for both cancellous bone and SCT, tissue penetration was lower on the infected side. Tissue specific targets for bone and soft tissue infections have not been established for vancomycin, but in plasma a 24-h (1,440 min) steady state target ratio of AUC/MIC ! 24,000 (corresponding to a ratio of 400 when AUC is given in h Á mg/ml) for vancomycin has been associated with clinical success. 38 For vancomycin, most orthopaedic pathogens exhibit relevant MICs in the range of 0.5-2 mg/l. 39 As our measurements were obtained over 8-h (480 min) and before achievement of steady state, the present single-dose study setup does not allow for a direct comparison to established targets. Nonetheless, it VANCOMYCIN BONE PENETRATION IN OSTEOMYELITIS seems unlikely that sufficient target site concentrations can be achieved in osteomyelitis complicated with metaphyseal cavities. Appreciating the toxicity of vancomycin, merely increasing doses is hardly a safe solution. 40 Consequently, the findings in this study supports that the presence of metaphyseal cavities is an indication for surgical debridement in acute osteomyelitis.
Already 5 days after inoculation in this porcine model, significantly impaired penetration of vancomycin to all compartments in the infected leg was found. Interestingly, though not completely significant, a difference was also noted between cancellous bone in the infected and the healthy leg with the poorest penetration found in the infected leg. This finding may indicate that vancomycin bone penetration decreases with the progression of the infection. Though such a correlation would be better investigated with a different study setup, it supports the importance of early diagnosis and initiation of antimicrobial treatment in the management of acute osteomyelitis.
As it has been shown for other tissues, the antimicrobial penetration may differ significantly between drugs. 31, [41] [42] [43] In an analogous study where cefuroxime was investigated, tissue penetration ratios were indeed higher for all tissues compared to the findings for vancomycin in the present study. 26 This indicate that selection of antimicrobials in the treatment of bone infections should not only be based on the antimicrobial sensitivity of the invading pathogen, but also on the specific bone pharmacokinetics of the drug. In turn, this stresses the importance of studies evaluating bone penetration of relevant antimicrobials. The findings in the present porcine osteomyelitis model suggest that cefuroxime may be more suitable for treatment of osteomyelitis compared to vancomycin when using standard dosing.
The assessment of antimicrobial bone pharmacokinetics during infection is challenged not only by the heterogeneous clinical presentation of osteomyelitis but also by the shortness of ideal sampling methods. Traditionally, bone pharmacokinetics of antimicrobials has been investigated using bone biopsies. 13 As opposed to this approach, MD allows for continuous sampling of the unbound extracellular fraction of drug, which, except for the rare cases where intracellular pathogens are present, is the compartment of interest. 44 Additionally, measurements can be continued after the end of surgery. 29 When conducting MDstudies, however, certain experimental factors must be considered and optimized. Of particular importance is the RR when evaluating absolute tissue concentrations. It is generally recommended that RR should exceed 20% as lower levels of RR are more exposed to a magnification of the variations associated with preanalytical sample handling and the chemical assay. 45 The resulting variation will increase exponentially with a decreasing RR. In the present study, measures were taken to optimize the RR by using MD probes with membranes as long as permitted by anatomical factors and by using a low perfusion rate, while maintaining acceptable sampling intervals and sample volumes sufficient for chemical analysis. This resulted in acceptable mean RR values in the range of 21.3-40.0%. The present application of MD in a validated porcine osteomyelitis model therefore seems to be an important step toward understanding antimicrobial penetration in osteomyelitis. 27 In conclusion, Staphylococcus aureus implant associated osteomyelitis was found to significantly reduce vancomycin bone penetration, especially in the implant cavity. Consequently, it may be unsafe to rely solely on vancomycin therapy when treating acute osteomyelitis. Particularly when metaphyseal cavities are present, surgical debridement seems necessary.
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